RAPGEF4 and pancreatic neoplasm: ESI-09 exhibits pan-EPAC inhibitory effects in in vitro and in vivo studies, where it was also found to hinder the progression of pancreatic cancer [24], prevent bacterial invasion in fatal rickettsioses [68] and regulate T-cell mediated suppression of the immune response [87].